GRAIL’s new FDA approved commercial facility in Durham, NC will have 120,000 SF of state-of-the-art high throughput DNA sequencing labs, over 5,000 SF of high-end refrigerated walking GMP warehouse and 75,000 SF of ambient GMP warehouse, data center, support facilities, and offices. This site will be dedicated to the early detection of cancer.
GRAIL’s purpose is to detect cancer early by combining high-intensity sequencing with the techniques of modern data science. GRAIL technology detects if tumors release cell-free nucleic acids (cfNAs) into the bloodstream. cfNAs are small fragments of DNA and RNA and reflect the genomic features of the tumor from which they originated. cfNAs are thought to be a direct measure of cancer and can be detectable in the bloodstream of people with cancer, potentially even before symptoms are present.
35 North was selected by GRAIL for the role of Project Management Partner and Owner Representative for the selection, design, construction, and commissioning.As the NC-based Owner’s Representative for GRAIL, we participated and provided input into all program design development meetings, ensured project scope was defined and incorporated into the design documents, identified critical decision points, made project recommendations, and positively impacted the quality, cost, and schedule of the Project.
35 North reviewed existing budgets and schedules, supported the selection process of the general contractor, and supported the selection process for all vendors/subcontractors outside GC scope of work. 35 North provided a Construction Manager to assure construction QC during the construction phase of the project, assisted in evaluating agreements between GRAIL and firms supporting the Project, identified cost savings strategies and value engineering alternatives, and developed a CQV strategy to meet GRAIL compliance and schedule needs.